Teamwork Financial Advisors LLC Has $1.46 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Teamwork Financial Advisors LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 49.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 18,729 shares of the medical device company’s stock after buying an additional 6,221 shares during the period. Teamwork Financial Advisors LLC’s holdings in DexCom were worth $1,457,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Blue Whale Capital LLP lifted its position in shares of DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC raised its holdings in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after buying an additional 11,075 shares in the last quarter. Brooktree Capital Management bought a new stake in shares of DexCom in the 3rd quarter worth approximately $683,000. National Pension Service grew its stake in shares of DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new stake in DexCom during the 3rd quarter valued at $650,000. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on DXCM shares. Canaccord Genuity Group upped their price objective on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Raymond James dropped their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.29.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Up 0.9 %

NASDAQ:DXCM opened at $87.09 on Thursday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a market cap of $34.02 billion, a PE ratio of 52.15, a price-to-earnings-growth ratio of 2.26 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a fifty day moving average price of $78.70 and a 200 day moving average price of $77.37.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.